Craig Bushnell Joins Planatome’s Executive Management Team

Planatome has appointed Craig Bushnell as Business Development and chief commercial officer (CCO). He is now responsible for overseeing Planatome’s commercial strategy, business development, and marketing efforts to foster growth and help the company market its low trauma surgical instruments.

A major focus of Bushnell’s role at Planatome will be to enhance the company’s strategic licensing agreements, enabling more healthcare and medical technology partners to integrate its surgical technology into their product lines. His vast expertise in business development, commercialization, and market positioning will be crucial in bolstering Planatome’s footprint in the surgical instruments sector, company executives said.

“Craig’s leadership arrives at a critical juncture as we work to broaden the reach of our technology. His proven success in commercializing medical innovations and forging impactful partnerships will help us accelerate our core purpose of improving the lives of others by delivering low trauma surgical instruments that yield unparalleled healing for patients,” Planatome CEO Tim Tobin stated.

Bushnell is a seasoned medical device executive and commercial leader with more than 25 years of experience developing and managing sales and marketing teams in emerging and highly competitive global medical device markets.

During his 18 years at Ethicon Endo-Surgery, Bushnell held various positions of increasing responsibility, including Sales and Marketing director at JJKK (Japanese affiliate) and Market Development director, helping drive commercial strategy and expand the firm’s global market presence.

He later served as vice president of Sales at Ulthera Inc., where he was instrumental in building the company from its startup phase through its acquisition. Most recently, he was Sales and Marketing vice president at GT Medical Technologies, where he created and led the commercial strategy, team build out, and product launch of GammaTile, a radioactive implant for malignant brain tumor treatment.

“I am excited to join Planatome and help accelerate its core purpose of improving lives through breakthrough surgical technology,” Bushnell said. “By applying semiconductor-level precision to medical instruments, we are delivering low-trauma surgical instruments that yield unparalleled healing for patients—especially those disproportionately affected by adverse scarring and chronic wounds. Leveraging my experience, I look forward to collaborating with the team and leading OEMs to expand opportunities, drive innovation, and make a lasting impact on surgical outcomes worldwide.”

Planatome is a medical technology company specializing in advanced precision-surface technology that enhances surgical instruments by reducing trauma, improving surgical performance, and optimizing patient recovery. Through strategic licensing agreements, Planatome enables medical device manufacturers to integrate its proprietary surface-modification technology into their surgical platforms.